CRMD News and Press, CorMedix Inc. From 05/18/21

The market's recently volatility has made some investors step back and think about their holdings. While this bout of volatility may be temporary, it's always good to stick to stocks that have a higher potential for outperformance and avoid stocks that have a higher potential for underperform...

Elliott Management (Paul Singer) initiated position in Discovery (DISCK), Facebook (FB), Trade Desk (TTD), E2Open (ETWO), Ryanair (RYAAY) as per its latest 13F filing.Elliott cut its stake in F5 Networks (FFIV) and Franco-Nevada (FNV).The hedge fund reduced its position in CorMedix (CRMD) and...

Biopharmaceutical company, CorMEdix ([[CRMD]] -20.5%) losses tempo despite beating Q1 revenue consensus by $0.06M, reports revenue of $0.09M.Operating expenses surged 29% to $7.2M, compared to the same quarter last year.Company reported cash and short-term investments...

Gainers: MoSys (MOSY) +43%.HyreCar (HYRE) +41%.Vivint Smart Home (VVNT) +26%.DoorDash (DASH) +26%.Intrusion (INTZ) +26%.One Stop Systems (OSS) +24%.LifeMD (LFMD) +24%.Atea Pharmaceuticals (AVIR) +24%.Cricut (CRCT) +23%.SemiLEDs (LEDS) +20%.Losers: CorMedix (CRMD) -25%...

Gainers: LifeMD (LFMD) +26%, Bionano Genomics (BNGO) +21%, Atea Pharmaceuticals (AVIR) +17%, DermTech (DMTK) +16%, Aesthetic Medical International (AIH) +12%.Losers: CorMedix (CRMD) -27%, Solid Biosciences (SLDB) -22%, PolarityTE (PT...

CorMedix (CRMD) -27% on Q1 earnings releaseIZEA Worldwide (IZEA) -25% on Q1 earnings releasePlantronics (PLT) -22% on Q4 earnings releaseMonaker Group (MKGI) -18% after pricing equity offering at $2.50.Meten EdtechX Education (METX) -18%.Eloxx Pharmaceu...

CorMedix Inc. (CRMD) Q1 2021 Results Conference Call May 13, 2021 04:30 PM ET Company Participants Daniel Ferry - Investor Relations Khoso Baluch - Chief Executive Officer Thomas Nusbickel - Executive Vice President and Chief Commercial Officer Phoebe Mounts - Executive Vice President and Gen...

CorMedix (CRMD): Q1 GAAP EPS of -$0.20 misses by $0.02.Revenue of $0.09M (+28.6% Y/Y) beats by $0.06M.Press Release For further details see: CorMedix EPS misses by $0.02, beats on revenue

BERKELEY HEIGHTS, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for th...

CorMedix (CRMD) announces the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer.Nusbickel most recently served as Vice President of Market Access and Government Affairs at Coherus Biosciences. For further details see: CorMedix names...